Tag: anti-parkinson drugs market growth

Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

What is the Expected Growth Rate of the Anti-Parkinson Drugs Global Market Report 2024 Market from 2024 to 2033?

The anti-Parkinson drugs market has seen robust growth in recent years. It is forecasted to grow from $9.73 billion in 2023 to $10.43 billion in 2024, with a CAGR of 7.2%. This growth can be attributed to the aging population, increased prevalence of the disease, better healthcare infrastructure, and advancements in research.

The anti-parkinson drugs market is expected to grow strongly, reaching $13.36 billion by 2028 at a CAGR of 6.4%. Growth is fueled by increased awareness, biotechnological advancements, and emerging markets. Key trends include investment in R&D, personalized medicine, disease-modifying therapies, and telemedicine.

Claim Your Free Sample of the Global Anti-Parkinson Drugs Global Market Report 2024 Market Report Today!

https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

What Key Factors Are Fueling the Growth of the Anti-Parkinson Drugs Global Market Report 2024 Market?

The increasing number of elderly individuals and the rising incidence of Parkinson’s disease (PD) are expected to drive the growth of the anti-Parkinson drugs market. PD is most common in individuals over 60 years old, and with a growing geriatric population, the demand for anti-Parkinson drugs is increasing. The WHO projects that by 2030, one in six people will be over 60, and by 2050, this number will double, further fueling the market for PD treatments.

What Are the Major Segments of the Anti-Parkinson Drugs Global Market Report 2024 Market?

1) By Drugs Class: Levodopa/Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs

2) By Route of Administration: Oral, Injection, Transdermal

3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

What New Trends Are Transforming the Anti-Parkinson Drugs Global Market Report 2024 Market?

In the anti-Parkinson drugs market, companies are working on products like Safinamide to enhance patient care. Safinamide, approved by India’s Drug Controller General in April 2021, is used to improve the quality of life for Parkinson’s disease patients and is an adjunct therapy to levodopa or carbidopa. This development aims to provide affordable and accessible treatments for Parkinson’s disease.

Order Now for Fast Delivery of Your Anti-Parkinson Drugs Global Market Report 2024 Market Report!

https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Which Regions Are Driving Growth in the Anti-Parkinson Drugs Global Market Report 2024 Market?

North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The Anti-Parkinson Drugs Global Market Report 2024 Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the anti-parkinson drugs global market report 2024 market, its market share, and analyzes key competitors along with their market positions.

The Table Of Content For The Anti-Parkinson Drugs Global Market Report 2024 Market Include

1. Anti-Parkinson Drugs Global Market Report 2024 Market Executive Summary

2. Anti-Parkinson Drugs Global Market Report 2024 Market Segments

3. Anti-Parkinson Drugs Global Market Report 2024 Market Size And Template Market Growth Rate

4. Key Anti-Parkinson Drugs Global Market Report 2024 Market Trends

5. Major Anti-Parkinson Drugs Global Market Report 2024 Market Drivers

……

25. Key Mergers And Acquisitions In The Anti-Parkinson Drugs Global Market Report 2024 Market

26. Top Anti-Parkinson Drugs Global Market Report 2024 Companies

27. Anti-Parkinson Drugs Global Market Report 2024 Market Opportunities And Strategies

28. Anti-Parkinson Drugs Global Market Report 2024 Market, Conclusions And Recommendations

29. Appendix

Discover Related Reports by The Business Research Company:

Central Nervous System Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report

Electrophysiology Devices And Equipment Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/electrophysiology-devices-and-equipment-global-market-report

Neurostimulation Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/neurostimulation-devices-global-market-report

Learn More About The Business Research Company

The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on:

The Business Research Company’s global market reports provide comprehensive analysis on the various markets in 27 industries across 60 geographies.

 The anti-parkinson drugs market has witnessed significant growth, reaching $9.73 billion in 2023 and projected to climb to $10.43 billion in 2024, reflecting a compound annual growth rate (CAGR) of 7.2%. Factors contributing to this growth include an aging population, increasing disease prevalence, advancements in healthcare infrastructure, and ongoing research initiatives.

Anticipated Growth and Key Drivers in the Coming Years

1. The market is poised for robust growth, reaching $13.36 billion by 2028, with a CAGR of 6.4%.
2. Key drivers include growing awareness, biotechnological advancements, and the expansion of emerging markets.
3. Major trends in the forecast period encompass investments in R&D, personalized medicine, disease-modifying therapies, drug repurposing, telemedicine and remote monitoring, biosimilars, and research collaborations.

Increasing Geriatric Population In The Anti-Parkinson Drugs Market

1. Geriatric Population as a Driving Factor
   • The rising geriatric population and the increasing incidence of Parkinson’s disease (PD) are anticipated to propel the demand for anti-parkinson drugs.
   • Globally, by 2030, 1 in 6 individuals will be 60 or older, and by 2050, this number is expected to double to 2.1 billion.
2. Regional Perspective: UK’s Aging Population
   • In the UK, the elderly population is projected to account for 24% of the total population (17.4 million people) by 2043.
   • This demographic shift underscores the significance of anti-parkinson drugs in addressing age-related health challenges.
3. Impact on Market Growth
   • The increasing geriatric population is a pivotal factor driving the growth of the anti-parkinson drugs market.

View More On The Anti-Parkinson Drugs Market Report 2024 – https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

Innovative Advancements In The Anti-Parkinson Drugs Market

1. Product Innovation for Improved Patient Services
   • Major companies are innovating products like Safinamide to enhance the quality of life for Parkinson’s patients.
   • Optimus Pharma launched Safinamide in April 2021, approved by the Drug Controller General of India, providing an affordable and accessible treatment option.
2. AbbVie’s Strategic Acquisition
   • In October 2023, AbbVie Inc. acquired Mitokinin for $110 million, aiming to bolster its neuroscience pipeline and offer new treatment options for Parkinson patients.
   • Mitokinin specializes in providing treatments for Parkinson’s disease.

Segmentation and Market Dynamics

1. Market Segmentation
   • The anti-parkinson drugs market is segmented by drug class (levodopa/carbidopa, dopamine receptor agonists, MAO-B inhibitors, COMT inhibitors, anticholinergics, and others), route of administration (oral, injection, transdermal), and distribution channel (hospital pharmacies, retailer pharmacies, online pharmacies).
2. Regional Dominance
   • North America emerged as the largest region in the anti-parkinson drugs market in 2023, highlighting the region’s pivotal role.
   • The Middle East is expected to be the fastest-growing region during the forecast period, indicating expanding opportunities.

Conclusion: A Promising Future for Anti-Parkinson Drugs As the anti-parkinson drugs market continues to evolve, driven by the increasing aging population and innovative advancements, the future holds promising opportunities. With a focus on research collaborations, personalized medicine, and technological innovations, stakeholders in the industry are well-positioned for sustained growth. The strategic acquisitions and product innovations outlined underscore the dynamic landscape of the market, shaping the future of Parkinson’s disease management.

Request A Sample Of The Global Anti-Parkinson Drugs Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=3462&type=smp